2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 327

Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis
Abstract Number: 328

A Study of Serum Electrolyte Levels after Denosumab Administration
Abstract Number: 329

Explore the Possible Mechanisms of 1,25(OH)2D3 on the Formation of Osteoclasts in Rheumatoid Arthritis
Abstract Number: 330

Safety of Denosumab in Postmenopausal Osteoporosis and in Cancer and Bone Metastase Treatment: A Systematic Review and Meta-Analysis
Abstract Number: 331

Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Abstract Number: 332

A Comparison of Electronic and Manual Fracture Risk Assessment Tools in Screening US Veterans at Risk for Osteoporosis
Abstract Number: 333

An Assessment of Bone Health and Fracture Risk in a Bariatric Surgery Population at an Urban Medical Center
Abstract Number: 334

Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study
Abstract Number: 335

High Risk of Osteoporosis and Long Term Joint Damage in Adults with a History of Juvenile Idiopathic Arthritis
Abstract Number: 336

The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab
Abstract Number: 337

Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability
Abstract Number: 338

Abaloparatide-SC Significantly Reduces Vertebral and Nonvertebral Fractures and Increases Bone Mineral Density (BMD) Regardless of Age, BMD T-Score, or Prior Fracture at Baseline
Abstract Number: 339

Assessment of High-Resolution Peripheral Quantitative Computed Tomography Parameters and Markers of Bone Metabolism in Community-Dwelling Elderly with and without Vertebral Fractures – the Sao Paulo Ageing & Health Study
Abstract Number: 340

Hydroxychloroquine: A Potential Treatment for Osteoporosis By Osteoclast Inhibition!
Abstract Number: 341

Evaluation of 25-Hydroxyvitamin D Levels in Rheumatologic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].